MML Investors Services LLC Increases Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

MML Investors Services LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.1% during the 3rd quarter, Holdings Channel reports. The firm owned 5,361 shares of the medical research company’s stock after purchasing an additional 159 shares during the quarter. MML Investors Services LLC’s holdings in Bio-Rad Laboratories were worth $1,794,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Avior Wealth Management LLC grew its holdings in shares of Bio-Rad Laboratories by 3.3% in the third quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock valued at $334,000 after acquiring an additional 32 shares in the last quarter. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC increased its holdings in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Bio-Rad Laboratories by 9.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock worth $259,000 after acquiring an additional 82 shares during the period. Finally, Quarry LP boosted its stake in Bio-Rad Laboratories by 38.1% in the third quarter. Quarry LP now owns 297 shares of the medical research company’s stock valued at $99,000 after acquiring an additional 82 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada raised their price target on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a research note on Monday, December 9th. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target on the stock. Citigroup upped their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Stock Down 1.7 %

Shares of NYSE:BIO opened at $337.28 on Wednesday. The company has a market cap of $9.44 billion, a price-to-earnings ratio of -12.34 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99. The firm has a fifty day moving average price of $341.35 and a two-hundred day moving average price of $322.07. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.33 EPS. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.